Taken together, we discovered that OTUD6B increased the stability and activity of both pVHL wild type and missense mutants in ccRCC, which provided a potential therapeutic strategy for ccRCC with VHL mutations. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.